First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.
Reinhard DummerPhilippa CorrieRalf GutzmerTarek M MeniawyMichele Del VecchioCeleste LebbèMichele GuidaCaroline DutriauxBrigitte DrenoNicolas MeyerPier Francesco FerrucciStéphane DalleMuhammad Adnan KhattakJean-Jacques GrobKaren BriscoeJames M G LarkinSandrine MansardThierry LesimpleMassimo GuidoboniSilvia SabatiniErika RichtigRudolf HerbstMaurice LoboMargarita AskelsonPaolo Antonio AsciertoMichele MaioPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Nivolumab plus ipilimumab followed by nivolumab monotherapy was tolerable in patients with advanced melanoma and poor prognostic characteristics. Efficacy was similar between the all-treated population and patients with brain metastases. Reduced efficacy was observed in patients with ECOG PS 2, ocular/uveal melanoma, and/or mucosal melanoma, highlighting the continued need for novel treatment options for these difficult-to-treat patients.